JP2022523524A5 - - Google Patents
Info
- Publication number
- JP2022523524A5 JP2022523524A5 JP2021549919A JP2021549919A JP2022523524A5 JP 2022523524 A5 JP2022523524 A5 JP 2022523524A5 JP 2021549919 A JP2021549919 A JP 2021549919A JP 2021549919 A JP2021549919 A JP 2021549919A JP 2022523524 A5 JP2022523524 A5 JP 2022523524A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion protein
- amino acid
- gpc3
- ability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19000100.8 | 2019-02-26 | ||
| EP19000100 | 2019-02-26 | ||
| PCT/EP2020/054821 WO2020173897A1 (en) | 2019-02-26 | 2020-02-25 | Novel fusion proteins specific for cd137 and gpc3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523524A JP2022523524A (ja) | 2022-04-25 |
| JP2022523524A5 true JP2022523524A5 (enExample) | 2022-12-13 |
| JP7476219B2 JP7476219B2 (ja) | 2024-04-30 |
Family
ID=65685094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549919A Active JP7476219B2 (ja) | 2019-02-26 | 2020-02-25 | Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12486330B2 (enExample) |
| EP (1) | EP3931209A1 (enExample) |
| JP (1) | JP7476219B2 (enExample) |
| KR (1) | KR20210133254A (enExample) |
| CN (1) | CN113474359B (enExample) |
| AU (1) | AU2020229436B2 (enExample) |
| BR (1) | BR112021016829A2 (enExample) |
| CA (1) | CA3124441A1 (enExample) |
| IL (1) | IL284687B2 (enExample) |
| MA (1) | MA55069A (enExample) |
| MX (1) | MX2021010039A (enExample) |
| SG (1) | SG11202106353VA (enExample) |
| WO (1) | WO2020173897A1 (enExample) |
| ZA (1) | ZA202104287B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3946417A1 (en) * | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
| JP2024513264A (ja) * | 2021-04-05 | 2024-03-22 | サイトヴィア セラピューティクス， エルエルシー | Ｎｋｐ４６及びｇｐｃ３を標的とする二重特異性抗体、並びにその使用方法 |
| AU2022260298A1 (en) * | 2021-04-23 | 2023-11-02 | Shanghai Henlius Biotech, Inc. | Anti-gpc3 antibodies, multispecific antibodies and methods of use |
| EP4341294A1 (en) * | 2021-05-21 | 2024-03-27 | BeiGene Switzerland GmbH | Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use |
| CN118103407A (zh) * | 2021-08-12 | 2024-05-28 | 上海才致药成生物科技有限公司 | 一种双特异性重组蛋白及其用途 |
| WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
| CN113912699A (zh) * | 2021-10-14 | 2022-01-11 | 江南大学 | 一种新型治疗乳腺癌的fgf类似物及其应用 |
| CN113956344A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种新型治疗肝癌的fgf类似物及其应用 |
| CN116640224A (zh) * | 2022-02-16 | 2023-08-25 | 北京免疫方舟医药科技有限公司 | Cd137抗体和cd40l的融合蛋白及其应用 |
| WO2023174401A1 (zh) * | 2022-03-18 | 2023-09-21 | 映恩生物制药（苏州）有限公司 | Gpc3抗体药物偶联物及其用途 |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| CN119613552B (zh) * | 2024-07-23 | 2025-11-28 | 艾可泰科(浙江)控股有限公司 | 一组抗人gpc3纳米抗体突变体及嵌合抗原受体和应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| DK1087778T3 (da) | 1998-06-08 | 2005-12-19 | Hoffmann La Roche | Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| AU2002335930B2 (en) | 2001-03-09 | 2005-07-28 | Morphosys Ag | Serum albumin binding moieties |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| US8598317B2 (en) | 2006-03-20 | 2013-12-03 | Technische Universitaet Muenchen | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 |
| EP2046820B1 (en) | 2006-08-01 | 2010-10-20 | Pieris AG | Muteins of tear lipocalin and methods for obtaining the same |
| US8497355B2 (en) * | 2007-09-28 | 2013-07-30 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
| MX337040B (es) * | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| AU2013334790A1 (en) * | 2012-10-23 | 2015-04-30 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using Wnt pathway-binding agents |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| JP6783797B2 (ja) * | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| CN114573680A (zh) * | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
| MX2017014730A (es) | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). |
| EP3298030B1 (en) * | 2015-05-18 | 2023-01-18 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
| WO2018087108A1 (en) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| WO2018129397A1 (en) * | 2017-01-06 | 2018-07-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
| CN110719920B (zh) * | 2017-06-14 | 2024-01-30 | 苏州丁孚靶点生物技术有限公司 | 蛋白质异二聚体及其用途 |
-
2020
- 2020-02-25 SG SG11202106353VA patent/SG11202106353VA/en unknown
- 2020-02-25 AU AU2020229436A patent/AU2020229436B2/en active Active
- 2020-02-25 BR BR112021016829-0A patent/BR112021016829A2/pt unknown
- 2020-02-25 CN CN202080016379.9A patent/CN113474359B/zh active Active
- 2020-02-25 CA CA3124441A patent/CA3124441A1/en active Pending
- 2020-02-25 IL IL284687A patent/IL284687B2/en unknown
- 2020-02-25 US US17/433,155 patent/US12486330B2/en active Active
- 2020-02-25 EP EP20705382.8A patent/EP3931209A1/en active Pending
- 2020-02-25 WO PCT/EP2020/054821 patent/WO2020173897A1/en not_active Ceased
- 2020-02-25 KR KR1020217030737A patent/KR20210133254A/ko active Pending
- 2020-02-25 MA MA055069A patent/MA55069A/fr unknown
- 2020-02-25 JP JP2021549919A patent/JP7476219B2/ja active Active
- 2020-02-25 MX MX2021010039A patent/MX2021010039A/es unknown
-
2021
- 2021-06-22 ZA ZA2021/04287A patent/ZA202104287B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523524A5 (enExample) | ||
| JP7827324B2 (ja) | インターロイキン－２バリアントおよびその使用方法 | |
| JP7529734B2 (ja) | ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質 | |
| JP7850417B2 (ja) | 新規インターロイキン－２バリアントおよびその二官能性融合分子 | |
| EP3180361B1 (en) | Recombinant antibody molecule and its use for target cell restricted t cell activation | |
| DK2536764T3 (en) | ANTI-CD28 HUMANIZED ANTIBODIES | |
| JP2021533203A5 (enExample) | ||
| JP7536294B2 (ja) | 抗体のＦｃ領域改変体 | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| JP2021506291A (ja) | 改変されたｉｌ−２ ｆｃ融合タンパク質 | |
| JP2019502694A (ja) | 二特異性抗体基幹 | |
| JP2018510623A (ja) | Ｎｋｇ２ｄ及び腫瘍関連抗原に対する二価抗体 | |
| KR20160034404A (ko) | Ｆc-함유 폴리펩타이드의 안정화 | |
| JP2018519803A5 (enExample) | ||
| JP2018515085A5 (enExample) | ||
| CN110382537B (zh) | 抗体结构域的优选配对 | |
| CN111699201A (zh) | 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法 | |
| JP2025160405A (ja) | 特異的結合分子 | |
| EP1737963A1 (fr) | Utilisation du gene codant la chaine beta de la proteine c4bp dans la production de proteines dimeriques recombinantes | |
| JP2023542049A (ja) | インターロイキン－２ムテイン及びその使用 | |
| RU2021121116A (ru) | Новые слитые белки, специфические в отношении cd137 и gpc3 | |
| CN115702169A (zh) | 包含促红细胞生成素多肽的融合蛋白 | |
| WO2021143733A1 (zh) | 一种融合蛋白及其制法和用途 | |
| CN115551538A (zh) | 干扰IL-1β受体信号转导的药剂 | |
| CN112969477A (zh) | 改善肽的血液动力学的方法 |